MAPK1 and Miyoshi myopathy: In vivo, neutralizing anti-VEGF-A antibody (Figure 3), and more efficaciously, anti-VEGFR-2 antibody (Figure 3) inhibits the constitutive autophosphorylation of both VEGFR-2 and the associated extracellular signal-regulated kinase-2 (ERK-2), proliferation, and capillarogenesis ability in MM ECs [72,73].